Trevena to Present at the JMP Securities Life Sciences Conference
CHESTERBROOK, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. will participate in a fireside chat at the JMP Securities Life Sciences Conference being held virtually June 16 - 17, 2021.
|Date:||Wednesday, June 16, 2021|
|Time:||1:30 pm Eastern Time|
|Presenter:||Carrie Bourdow, President & CEO|
A link to the webcast will be available on the Events page of the Investors section of the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar. A replay of the presentation will be archived on the website and available for approximately 30 days following the event. Please contact your JMP Securities representative to schedule virtual one-on-one meetings with Trevena during the conference.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.
For more information, please visit www.Trevena.com.
Released June 9, 2021